Gary S. Jacob - 10 Jun 2021 Form 4 Insider Report for Cardiff Oncology, Inc. (CRDF)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
15 Jun 2021, 10:06:43 UTC
Prior SEC filing
20 May 2021
Next SEC filing
05 Jan 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Gary Jacob

Key filing fact

Gary S. Jacob filed Form 4 for Cardiff Oncology, Inc. (CRDF) on 15 Jun 2021.

Key facts

  • This page summarizes Gary S. Jacob's Form 4 filing for Cardiff Oncology, Inc. (CRDF).
  • 8 reported transactions and 8 derivative rows are listed below.
  • Accepted by SEC: 15 Jun 2021, 10:06.

Change

  • Previous filing in this sequence was filed on 20 May 2021.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRDF transaction Derivative

Stock Options

Other

Transaction value
$0
Shares
+28,858
Change %
+61%
Price
$0.000000
Shares after
76,106
Date
10 Jun 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
28,858
Exercise price
$2.60
Footnotes
F1
CRDF transaction Derivative

Stock Options

Other

Transaction value
$0
Shares
+293
Change %
+0.39%
Price
$0.000000
Shares after
76,106
Date
10 Jun 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
293
Exercise price
$447.84
Footnotes
F2, F3
CRDF transaction Derivative

Stock Options

Other

Transaction value
$0
Shares
+218
Change %
+0.29%
Price
$0.000000
Shares after
76,106
Date
10 Jun 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
218
Exercise price
$316.08
Footnotes
F2
CRDF transaction Derivative

Stock Options

Other

Transaction value
$0
Shares
+223
Change %
+0.29%
Price
$0.000000
Shares after
76,106
Date
10 Jun 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
223
Exercise price
$516.96
Footnotes
F2
CRDF transaction Derivative

Stock Options

Other

Transaction value
$0
Shares
+223
Change %
+0.29%
Price
$0.000000
Shares after
76,106
Date
10 Jun 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
223
Exercise price
$372.96
Footnotes
F2
CRDF transaction Derivative

Stock Options

Other

Transaction value
$0
Shares
+530
Change %
+0.7%
Price
$0.000000
Shares after
76,106
Date
10 Jun 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
530
Exercise price
$51.84
Footnotes
F2
CRDF transaction Derivative

Stock Options

Other

Transaction value
$0
Shares
+755
Change %
+1%
Price
$0.000000
Shares after
76,106
Date
10 Jun 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
755
Exercise price
$21.60
Footnotes
F2
CRDF transaction Derivative

Stock Options

Other

Transaction value
$0
Shares
+44,734
Change %
+143%
Price
$0.000000
Shares after
76,106
Date
10 Jun 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
44,734
Exercise price
$2.48
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

In connection with the Reporting Person's departure from the Board of Directors, the Compensation Committee accelerated the vesting of 28,858 stock options to June 10, 2021 from June 17, 2021. In addition, the Compensation Committee extended the expiration date of the stock options to June 10, 2023.

Footnote F2

Expiration date of the stock options was extended to June 10, 2023.

Footnote F3

8,805 of the stock options vest immediately. 4,077 of the stock options vest on each of 2/25/2015 and 2016 and 4,076 of the stock options vest on 2/25/2017.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .